Adaptive Biotechnologies Corp

ADPT

$16.39

-74.3% last 12 months

Market Cap

$2.42 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$17.11 - $68.25

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

-12.73x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $2.42 Billion
Enterprise Value $2.01 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return -74.3%
52-Week High $68.25
52-Week Low $17.11
Beta 1.85
Outstanding Shares 141 Million
Avg 30 Day Volume 911 Thousand

Valuation

P/E Ratio -12.73
PEG -24.36
Earnings per Share -$1.37
Price to Sales Ratio 16.39
Price to Book Ratio 4.1
Revenue to Enterprise Value 13.7
EBIT to Enterprise Value -10.48
Total Debt to Enterprise Value 0.0
Debt to Equity 0.0

Profitability

Revenue $147 Million
Gross Profit $105 Million
EBIT -$192 Million
Net Income -$190 Million
Profit Margin -129.89%
Quarterly Earnings Growth (YoY) +52.2%
Return on Equity -29.23%
Return on Assets -19.18%
Return on Invested Capital -22.02%

Insider trades

No purchases

58,403 shares sold (14 transactions)

No purchases

52,946 shares sold (11 transactions)

No purchases

18,763 shares sold (4 transactions)

No purchases

1,021 shares sold (1 transactions)

Q2 2021 Q3 2021 Q4 2021 Q1 2022

About Adaptive Biotechnologies Corp

CEO: Chad Robins

Industry: Biological Product (except Diagnostic) Manufacturing

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Its proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have three commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

Similar stocks

HCA Healthcare Inc
HCA Healthcare Inc
Premier Inc - Class A
Premier Inc - Class A
Community Health Systems, Inc.
Community Health Systems, Inc.
Select Medical Holdings Corporation
Select Medical Holdings Corporation

News